​

Roivant Sciences (ROIV) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Roivant Sciences Revenue Highlights

Latest Revenue (Y)

$124.80M

Latest Revenue (Q)

$55.13M

Main Segment (Y)

Product

Roivant Sciences Revenue by Period

Roivant Sciences Revenue by Year

DateRevenueChange
2024-03-31$124.80M103.65%
2023-03-31$61.28M10.84%
2022-03-31$55.29M132.34%
2021-03-31$23.80M-64.85%
2020-03-31$67.69M2812.61%
2019-03-31$2.32M-

Roivant Sciences generated $124.80M in revenue during NA 2024, up 103.65% compared to the previous quarter, and up 5369.84% compared to the same period a year ago.

Roivant Sciences Revenue by Quarter

DateRevenueChange
2024-06-30$55.13M90.57%
2024-03-31$28.93M-22.11%
2023-12-31$37.14M0.11%
2023-09-30$37.10M71.57%
2023-06-30$21.62M-21.01%
2023-03-31$27.38M60.54%
2022-12-31$17.05M36.06%
2022-09-30$12.53M190.18%
2022-06-30$4.32M-53.17%
2022-03-31$9.22M-62.11%
2021-12-31$24.34M74.03%
2021-09-30$13.99M80.83%
2021-06-30$7.74M-48.93%
2021-03-31$15.15M163.41%
2020-12-31$5.75M334.62%
2020-09-30$1.32M-16.05%
2020-06-30$1.58M-97.50%
2020-03-31$62.95M-

Roivant Sciences generated $55.13M in revenue during Q1 2025, up 90.57% compared to the previous quarter, and up 201.39% compared to the same period a year ago.

Roivant Sciences Revenue Breakdown

Roivant Sciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceMar 24Mar 23
Product$75.06M$28.01M

Roivant Sciences's latest annual revenue breakdown by segment (product or service), as of Mar 24: Product (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 23Sep 23Jun 23
Product Revenue, Net$20.67M$18.42M$16.66M

Roivant Sciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Product Revenue, Net (100.00%).

Roivant Sciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BGNEBeiGene$2.46B$929.17M
APLSApellis Pharmaceuticals$366.28M$176.57M
ASNDAscendis Pharma$266.72M$95.89M
BPMCBlueprint Medicines$249.38M$128.18M
ROIVRoivant Sciences$124.80M$55.13M
KRYSKrystal Biotech$50.70M$83.84M
RVMDRevolution Medicines$11.58M-
PLRXPliant Therapeutics$1.58M-
LYRALyra Therapeutics$1.56M$195.00K
PHATPhathom Pharmaceuticals$682.00K$16.35M
VRDNViridian Therapeutics$314.00K$86.00K
CGEMCullinan Oncology--
DAWNDay One Biopharmaceuticals-$20.07M
INZYInozyme Pharma--
SNDXSyndax Pharmaceuticals-$12.50M
AKROAkero Therapeutics--

ROIV Revenue FAQ

What is Roivant Sciences’s yearly revenue?

Roivant Sciences's yearly revenue for 2024 was $124.8M, representing an increase of 103.65% compared to 2023. The company's yearly revenue for 2023 was $61.28M, representing an increase of 10.84% compared to 2022. ROIV's yearly revenue for 2022 was $55.29M, representing an increase of 132.34% compared to 2021.

What is Roivant Sciences’s quarterly revenue?

Roivant Sciences's quarterly revenue for Q1 2025 was $55.13M, a 90.57% increase from the previous quarter (Q4 2024), and a 154.96% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $28.93M, a -22.11% decrease from the previous quarter (Q3 2024), and a 5.68% increase year-over-year (Q4 2023). ROIV's quarterly revenue for Q3 2024 was $37.14M, a 0.11% increase from the previous quarter (Q2 2024), and a 117.80% increase year-over-year (Q3 2023).

What is Roivant Sciences’s revenue growth rate?

Roivant Sciences's revenue growth rate for the last 3 years (2022-2024) was 125.73%, and for the last 5 years (2020-2024) was 84.37%.

What are Roivant Sciences’s revenue streams?

Roivant Sciences's revenue streams in r 24 are Product

What is Roivant Sciences’s main source of revenue?

For the fiscal year ending Mar 24, the largest source of revenue of Roivant Sciences was Product. This segment made a revenue of $75.06M, representing 100.00% of the company's total revenue.